Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: Meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results

Journal of Clinical Pharmacology

Volumn 52, Issue 10, 2012, Pages 1494-1505

  Gibbs, John P ^a   Fredrickson, Jill ^c   Barbee, Todd ^c   Correa, Itzela ^c   Smith, Brian ^a   Lin, Shao Lee ^b   Gibbs, Megan A ^a  

^a Pharmacokinetics and Drug Metabolism ^*  (United States)

^b AMGEN INC   (United States)

^c Pharsight A Cetara Company   (United States)

Author keywords

diabetes; DPP 4; drug development; meta analysis; pharmacodynamics; Pharmacokinetics; PK PD

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SY 322; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; STEADY STATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADAMANTANE; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, BIOLOGICAL; NITRILES; PIPERIDINES; PYRAZINES; PYRROLIDINES; TREATMENT OUTCOME; TRIAZOLES; URACIL;

EID: 84870422266     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011420153     Document Type: Article

References (68)

1. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008 ; 2: CD006739
2. Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009 ; 122: S3 - S10
3. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006 ; 3: 153-165
4. Ahren B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin Emerging Drugs. 2008 ; 13: 593-607
5. Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009 ; 57: 2011-2019
6. Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med. 2010 ; 123: S28 - S37
7. Horsham, United Kingdom: Novartis Europharm ; 2008 :
8. Whitehouse Station, New Jersey: Merck & Co Inc ; 2010 :
9. Princeton, New Jersey: Bristol-Myers Squibb ; 2009 :
10. Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008 ; 30: 499-512
11. Sunkara G, Sabo R, Wang Y, et al. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol. 2007 ; 47: 1152-1158
12. Karim A, Covington P, Christopher R, et al. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. Int J Clin Pharmacol Ther. 2010 ; 48: 46-58
13. Thomas L, Eckhardt M, Langkopf E, et al. (R)-8-(3-amino-piperidin-1-yl)- 7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008 ; 325: 175-182
14. Severino ME, Dubose RF, Patterson SD. A strategic view on the use of pharmacodynamic biomarkers in early clinical drug development. Idrugs. 2006 ; 9: 849-853
15. Sultana SR, Marshall S, Davis J, Littman BH. Experiences with dose finding in patients in early drug development: the use of biomarkers in early decision making. Ernst Schering Res Found Workshop. 2007 ; (59). 65-79
16. Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther. 2007 ; 82: 21-32
17. Mandema JW, Cox E, Alderman J. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain: results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia. 2005 ; 25: 715-725
18. Mandema JW, Hermann D, Wang W, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 ; 7: E513 - E522
19. Hing J, Perez-Ruixo JJ, Stuyckens K, et al. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia. Clin Pharmacol Ther. 2008 ; 83: 130-143
20. Luu K, Raber S, Nickens D, Vicini P. A model-based meta-analysis of the effect of latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension. Clin Pharmacol Ther. 2010 ; 87: 421-425
21. Wang Y, Sung C, Dartois C, et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther. 2009 ; 86: 167-174
22. Rohatagi S, Carrothers TJ, Jin J, et al. Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs. J Clin Pharmacol. 2008 ; 48: 1420-1429
23. Boeckmann AJ, Sheiner LB, Beal SL NONMEM User's Guide: Part V. San Francisco: University of California, San Francisco ; 1994 :
24. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001 ; 28: 171-192
25. Krishna R, Herman G, Wagner JA. Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. AAPS J. 2008 ; 10: 401-409
26. Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiat. 2001 ; 158: 1843-1849
27. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiat. 2004 ; 161: 826-835
28. Farde L, Nordstrom AL, Wiesel FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiat. 1992 ; 49: 538-544
29. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiat. 1999 ; 156: 286-293
30. Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiat. 1999 ; 156: 869-875
31. Bressan RA, Jones HM, Ell PJ, Pilowsky LS. Dopamine D(2) receptor blockade in schizophrenia. Am J Psychiat. 2001 ; 158: 971-972
32. Landersdorfer CB, Jusko WJ. Pharmacokinetic/pharmacodynamic modeling in diabetes mellitus. Clin Pharmacokinet. 2008 ; 47: 417-448
33. de Winter W, DeJongh J, Post T, et al. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus. J Pharmacokinet Pharmacodyn. 2006 ; 33: 313-343
34. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999 ; 281: 2005-2012
35. Shang EY, Gibbs MA, Landen JW, et al. Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder. J Pharmacokinet Pharmacodyn. 2009 ; 36: 63-80
36. Benincosa LJ, Jusko WJ. Novel method of treatment. Organization. 1999 ;:
37. Ahn JE, French JL. Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation. J Pharmacokinet Pharmacodyn. 2010 ; 37: 179-201
38. Roy RS, Wu JK, Eiermann GJ, et al. Plasma DPP-4 inhibition by sitagliptin and other DPP-4 inhibitors correlates with and predicts glucose lowering efficacy. Paper presented at: American Diabetes Association ; 2009 New Orleans, LA ; 2009..
39. Hanefeld M. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Paper presented at: American Diabetes Association ; 2005 San Diego, CA ; 2005..
40. Nonaka K, Kakikawa T, Sato A, et al. Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, as monotherapy in Japanese patients with type 2 diabetes. Paper presented at: American Diabetes Association ; 2006 Washington, DC ; 2006..
41. Raz I, Hanefeld M, Xu L, et al. Sitagliptin monotherapy improved glycemic control and beta-cell function after 18 weeks in patients with type 2 diabetes (T2DM). Paper presented at: American Diabetes Association ; 2006 Washington, DC ; 2006..
42. White House Station, NJ: Merck & Co, Inc ; 2006 :
43. Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004 ; 89: 2078-2084
44. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005 ; 7: 692-698
45. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res. 2006 ; 38: 423-428
46. Matikainen N, Manttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006 ; 49: 2049-2057
47. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007 ; 30: 217-223
48. Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed {beta}-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab. 2008 ; 93: 103-109
49. European Public Assessment: Galvus H-C-771. http://www.ema.europa.eu/ docs/en/GB/document/library/EPAR/-/Scientific/Discussion/human/000771/ WC500020330.pdf
50. Fleck P, Christopher R, Covington P, Mekki QA. Efficacy and safety of alogliptin monotherapy over 12 weeks in patients with type 2 diabetes. Paper presented at: American Diabetes Association ; 2008 June 6-10, 2008 San Francisco, CA ; 2008..
51. Defronzo R, Fleck P, Wilson C, Mekki QA. Alogliptin monotherapy improves glycemic control in patients with type 2 diabetes. Paper presented at: American Diabetes Association ; 2008 June 6-10, 2008 San Francisco, CA ; 2008..
52. Merck. Press release. 2006. Washington, District of Columbia. Newly Released Phase III Studies for Januvia.tm
53. Karasik A, Charbonnel B, Liu J, et al. Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes. Paper presented at: American Diabetes Association ; 2006 Washington, DC ; 2006..
54. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007 ; 9: 194-205
55. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007 ; 30: 1979-1987
56. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004 ; 27: 2874-2880
57. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007 ; 30: 890-895
58. Dejager S, Lebeaut A, Cowin GJ, Schweizer A. Sustained reduction in HbA1c during one year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Paper presented at: American Diabetes Association ; 2006 June 9-13, 2006 Washington, DC ; 2006..
59. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008 ; 10: 82-90
60. Nauck M, Ellis G, Fleck P, Wilson C, Mekki QA. Efficacy and safety of alogliptin added to metformin therapy in patients with type 2 diabetes. Paper presented at: American Diabetes Association ; 2008 San Francisco, CA ; 2008..
61. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007 ; 9: 166-174
62. Pratley RE, Kipnes M, Fleck P, Wilson C, Mekki QA. Alogliptin added to sulfonylurea therapy in patients with type 2 diabetes reduces HbA1c without increasing hypoglycemia. Paper presented at: American Diabetes Association ; 2008 San Francisco, CA ; 2008..
63. European Association for the Study of Diabetes 2008 Highlights, Investor Teleconference ; 2008 Rome, Italy ; 2008..
64. Herman GA, Hanefeld M, Wu M, et al. Effect of MK-0431, a dipeptidyl peptidase (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Paper presented at: American Diabetes Association ; 2005 San Diego, CA ; 2005..
65. He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007 ; 47: 633-641
66. He YL, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2007 ; 46: 577-588
67. Boulton DW. Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects. Paper presented at: American Diabetes Association ; 2007 Chicago, IL ; 2007..
68. Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008 ; 30: 513-527